Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Announces Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) issued its quarterly earnings results on Tuesday. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.15, Zacks reports. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.93%. Bayer Aktiengesellschaft updated its FY 2026 guidance to 1.200-1.346 EPS.

Bayer Aktiengesellschaft Stock Performance

BAYRY traded up $0.37 on Tuesday, reaching $11.25. The stock had a trading volume of 408,939 shares, compared to its average volume of 1,249,461. The business’s 50-day moving average price is $11.31 and its two-hundred day moving average price is $10.91. The company has a market cap of $44.21 billion, a P/E ratio of -10.14 and a beta of 0.62. Bayer Aktiengesellschaft has a 12-month low of $6.20 and a 12-month high of $14.85. The company has a current ratio of 1.01, a quick ratio of 0.63 and a debt-to-equity ratio of 1.22.

Wall Street Analyst Weigh In

BAYRY has been the topic of a number of research reports. UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th. Zacks Research raised shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Friday. Finally, DZ Bank raised Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 9th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Bayer Aktiengesellschaft currently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.